A study testing whether a new weekly shot from Lilly, tirzepatide, can calm gut inflammation.

This is the exact wording from ClinicalTrials.gov, including clinical measures (lab values, imaging scores). Bring it to your doctor if any of it is unclear.

Key inclusion criteria

• Have had an established diagnosis of UC for >=3 months before baseline which includes endoscopic evidence of UC and a histopathology report that supports a diagnosis of UC.
• Have moderately to severely active UC as defined by a modified Mayo score (mMS) of 5 to 9 points and endoscopic subscore (ES) of 2 to 3 (confirmed by central review) within 21 days before baseline.
• Participants with a history of UC for greater than or equal to 8 years who have had a surveillance colonoscopy completed within 1 year prior to baseline must have documented negative results for colorectal dysplasia and cancer.
• Have obesity, [body mass index (BMI) 30 kilograms per meter squared (kg/m2)]
• Have overweight (BMI >=27 kg/m2 to <30 kg/m2) and in the presence of at least 1 of these weight-related comorbid conditions:

Key exclusion criteria

• Have a current diagnosis of:
• Crohn's disease
• inflammatory bowel disease (IBD) unclassified (formerly known as indeterminate colitis), or
• primary sclerosing cholangitis.
• Have had or will need bowel resection or intestinal or intra-abdominal surgery.